

Colorectal Cancer Focused Panel Tests via Circulating Tumor DNA (ctDNA)

- I. Colorectal cancer focused panel tests via circulating tumor DNA (ctDNA) (81210, 81275, 81311, 81403, 81479) are considered **medically necessary** when:
 - A. The member has a diagnosis of metastatic colorectal adenocarcinoma, **AND**
 - B. Panel includes *KRAS*, *NRAS*, and *BRAF* analysis, **AND**
 - C. At least one of the following:
 1. The member is medically unfit for invasive tissue sampling (biopsy), **OR**
 2. Biopsy was performed, but material was insufficient for molecular analysis, **OR**
 3. Biopsy was performed, but molecular analysis was not able to be completely assessed on tissue due to availability of testing methodologies.
- II. Colorectal cancer focused panel tests via circulating tumor DNA (ctDNA) (81210, 81275, 81311, 81403, 81479) are considered **investigational** for all other indications.

NOTES AND DEFINITIONS

1. **Cell-free circulating tumor DNA (ctDNA)** is fragmented, tumor-derived DNA circulating in the bloodstream that is not being carried in a cell. ctDNA derives either directly from the tumor or from circulating tumor cells.

REFERENCES

1. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Colon Cancer. Version 2.2023.
https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf.